AU1920501A - The use of caspase 9 inhibitors to treat ocular neural pathology - Google Patents

The use of caspase 9 inhibitors to treat ocular neural pathology

Info

Publication number
AU1920501A
AU1920501A AU19205/01A AU1920501A AU1920501A AU 1920501 A AU1920501 A AU 1920501A AU 19205/01 A AU19205/01 A AU 19205/01A AU 1920501 A AU1920501 A AU 1920501A AU 1920501 A AU1920501 A AU 1920501A
Authority
AU
Australia
Prior art keywords
caspase
inhibitors
treat ocular
neural pathology
ocular neural
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU19205/01A
Inventor
Mark R Hellberg
Jon C Nixon
Iok-Hou Pang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Alcon Universal Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Universal Ltd filed Critical Alcon Universal Ltd
Publication of AU1920501A publication Critical patent/AU1920501A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU19205/01A 1999-12-03 2000-11-16 The use of caspase 9 inhibitors to treat ocular neural pathology Abandoned AU1920501A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16891499P 1999-12-03 1999-12-03
US60168914 1999-12-03
PCT/US2000/031471 WO2001039792A2 (en) 1999-12-03 2000-11-16 The use of caspase 9 inhibitors to treat ocular neural pathology

Publications (1)

Publication Number Publication Date
AU1920501A true AU1920501A (en) 2001-06-12

Family

ID=22613475

Family Applications (1)

Application Number Title Priority Date Filing Date
AU19205/01A Abandoned AU1920501A (en) 1999-12-03 2000-11-16 The use of caspase 9 inhibitors to treat ocular neural pathology

Country Status (2)

Country Link
AU (1) AU1920501A (en)
WO (1) WO2001039792A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2815541B1 (en) * 2000-10-24 2008-02-29 Lipha USE OF PERICYTE APOPTOSIS INHIBITORS FOR THE TREATMENT AND / OR PREVENTION OF DIABETIC RETINOPATHY
EP1568359A4 (en) * 2002-12-04 2011-05-18 Santen Pharmaceutical Co Ltd Drug delivery system using subconjunctival depot
FR2878522B1 (en) 2004-12-01 2008-04-18 Merck Sante Soc Par Actions Si NEW SPECIFIC INHIBITORS OF CASPAS-10
EP2106445A2 (en) * 2006-12-01 2009-10-07 Loma Linda University Medical Center Inhibition of brain enzymes involved in cerebral amyloid angiopathy and macular degeneration
US10752593B2 (en) 2018-12-28 2020-08-25 Endogena Therapeutics, Inc. Compounds for use as therapeutically active substances in the treatment of retinal diseases
WO2011133964A2 (en) 2010-04-23 2011-10-27 Massachusetts Eye And Ear Infirmary Methods and compositions for preserving photoreceptor and retinal pigment epithelial cells
US20140024598A1 (en) * 2010-11-01 2014-01-23 Demetrios Vavvas Methods and compositions for preserving retinal ganglion cells
US20140357570A1 (en) 2011-10-21 2014-12-04 Massachusetts Eye And Ear Infirmary Compositions comprising necrosis inhibitors, such as necrostatins, alone or in combination, for promoting axon regeneration and nerve function, thereby treating cns disorders
EP2861243A4 (en) * 2012-06-13 2016-04-27 Univ Columbia Intranasal delivery of cell permeant therapeutics for the treatment of edema
EP3481395A4 (en) * 2016-07-11 2020-05-13 The Trustees of Columbia University in the City of New York Ocular delivery of cell permeant therapeutics for the treatment of retinal edema
WO2020223212A2 (en) * 2019-04-29 2020-11-05 The Trustees Of Columbia University In The City Of New York Compositions and methods for preventing or reducing inflammation by inhibiting caspase-9

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5348945A (en) * 1990-04-06 1994-09-20 Wake Forest University Method of treatment with hsp70
US6153591A (en) * 1998-03-16 2000-11-28 Cytovia, Inc. Dipeptide caspase inhibitors and the use thereof
US6403765B1 (en) * 1998-06-16 2002-06-11 Thomas Jefferson University Truncated Apaf-1 and methods of use thereof

Also Published As

Publication number Publication date
WO2001039792A2 (en) 2001-06-07
WO2001039792A3 (en) 2002-05-10

Similar Documents

Publication Publication Date Title
AU6462500A (en) Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement
PL348059A1 (en) Compounds useful in the treatment of inflammatory diseases
AU7132998A (en) Substituted pyrrolopyridines useful in the treatment of inflammatory diseases
AU2639695A (en) Novel uses of triplex forming oligonucleotides for the treatment of human diseases
AU2001288251A1 (en) Methods and devices for optical stimulation of neural tissues
IL132318A0 (en) Substituted imidazoles useful in the treatment of inflammatory diseases
AU1920501A (en) The use of caspase 9 inhibitors to treat ocular neural pathology
AU2001256855A1 (en) Preparation for the prevention and treatment of ocular disorders
ZA951088B (en) Use of substituted arylcyclobutylalkylamine compounds in the treatment of seizures neurological disorders and neurological damage
AUPQ622600A0 (en) Treatment and/or prevention of ocular pain
AU5056099A (en) Compounds for use in the treatment of inflammation
AU5593398A (en) The use of inhibitors of tgf-beta's functions to ameliorate ocular pathology
AU7106300A (en) Treatment of skin disorders
AU4489397A (en) The use of calpain inhibitors to treat ocular neural pathology
AU4676099A (en) Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction
HUP0000785A3 (en) Ointment for the treatment of burns and other skin diseases
AU9278598A (en) Use of azole derivatives for the treatment of inflammatory skin conditions
ZA958558B (en) Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases
AU6281298A (en) Use of lofexidine in the treatment of behavioral disorders
AU4812393A (en) Use of rapamycin in the treatment of aids
AU7653600A (en) Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives for the treatment of multiple sclerosis
AU2566201A (en) Compounds and methods for the treatment of pain
GB9904081D0 (en) Improvements in or relating to the treatment or prevention of parasitic infestation
AU1022501A (en) Use of compositions for the caring treatment of the skin
AU2434297A (en) The use of 5-ht1b/1d agonists to treat ocular pain

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase